Nancy G.B. Agrawal is vice-president, pharmacokinetics, pharmacodynamics, and drug metabolism, Merck.

Nancy G.B. Agrawal

Predictive sciences—built on improved computational capabilities and a deeper understanding of human physiology—are allowing researchers to perform human studies prior to, and sometimes in place of, human clinical trials in order to predict drug outcomes. Representatives of the 

Translational & ADME Sciences Leadership Group (TALG)

 in the IQ Consortium review the basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process.

Pharmaceutical Technology's Regulatory Sourcebook 

When referring to this article, please cite it as H. Einolf ,et al., " Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling," 

Pharmaceutical Technology Regulatory Sourcebook

Articles

Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed. 